1
2
3

Information List

Good news! Wuxi Beta Pharmaceutical Technology Co., Ltd. was recognized as a "high-tech enterprise" for the third time"

2021-01-28

On January 22, 2021, the Office of the National High-tech Enterprise Certification Management Leading Group issued the "Reply on the Filing of the First Batch of High-tech Enterprises in Jiangsu Province in 2020" (Guo Ke Huo [2021] No. 39), Wuxi Beta Pharmaceutical Technology Co., Ltd. was recognized as a "high-tech enterprise" (ranked 4962). This is the third time that our company has been recognized as a "high-tech enterprise". Wuxi Beta Pharmaceutical Technology Co., Ltd. was founded in Jiangyin High-tech Zone on November 27, 2008 by Dr. Li Gang, winner of the second prize for national scientific and technological progress and an entrepreneurial talent studying in the United States. It is a high-tech private enterprise specializing in the research and development and industrialization of isotope labeling products and tracer technologies such as carbon -14(C14) and carbon -13(C13) in the field of nuclear technology application (isotope) in China, the main purpose is to apply the strategic nuclide C14 radioisotope labeling tracer technology to innovative medicine, pesticide research and development, biotechnology and medical testing. The company has 4000 square meters of isotope labeling laboratory, and has established research and development platforms such as the Nobel Prize Research Institute, "Jiangsu Enterprise Academician Workstation" and Jiangyin Beta Isotope Labeling Engineering Technology Research Center. It has 18 authorized technology patents and more than 400 isotope labeling products, most of which fill the gaps in China and some of which are international initiatives. The company has signed cooperation agreements with nuclear reactor units, domestic and foreign pharmaceutical and pesticide industry leaders, Cambridge isotope laboratory company of the United States, Swiss RCTRITECH company, etc., after more than ten years of technical research, it has created five "gold standard" products and technologies in the field of medicine and medical treatment. Especially in the field of C14 marking products and tracer technology, the localization of domestic C14 source materials has been realized for the first time, and the C14 marking of domestic innovative medicines and pesticides has been solved. C14 marking services have been provided to listed pharmaceutical and pesticide companies such as Hengrui Medicine, Koren Pharmaceutical and Lier Chemical, as well as dozens of leading pharmaceutical and pesticide metabolism units such as Shanghai Institute of Medicine, Chinese Academy of Sciences, Ecological Environment Research Center and Shenyang Institute of Chemical, widely praised by customers, it has doubled the growth of its main business for three consecutive years and established solutions for international shortages. The identification of "high-tech enterprise" is a recognition of Wuxi Beta's long-term focus on research and development and rapid growth. Beta people will forge ahead and make new achievements, making unique and important contributions to the development of innovative medicine, innovative pesticide and ecological environmental protection.

Our company was selected as a reserve enterprise for cultivating science and technology innovation board in Jiangyin city in 2020.

2020-04-30

[Good News] Wuxi Beta Approved Construction Project of Provincial Academician Workstation of Provincial Science and Technology Department and Education Department

2020-03-31

Congratulations to Wuxi Beta for Providing SH-1028 New Drug of Shenghe Pharmaceutical Co., Ltd. with Carbon 14 Isotope Labeling Service

2019-08-01

Congratulations to Wuxi Beta for providing the Koren Pharmaceutical KL060332 Capsule labeled with carbon 14 isotope, which has been accepted by the National Food and Drug Administration Clinical Trial Notice and FDA Drug Clinical Trial Application

2019-07-31

On July 25, 2019, Sichuan Kelun Pharmaceutical Co., Ltd., an A- share listed company, issued the notice on the company's KL060332 capsule obtaining clinical trial notice and the acceptance of SKB264 new drug clinical trial application. The innovative drug KL060332 capsule developed by the company's holding subsidiary Sichuan Kelun Botai Biopharmaceutical Co., Ltd. has obtained the clinical trial notice of the State Drug Administration, and the KLUSPharmaInc of the company's holding subsidiary. Has been submitted to the United States Food and Drug Administration (hereinafter referred to as FDA) antibody conjugate drugs (AntibodyD

Good news! The Party Branch of Wuxi Beta Pharmaceutical Technology Co., Ltd. was approved to be established.

2019-07-26

Recently, the Party Working Committee of Jiangyin High-tech Zone approved the establishment of the Party branch of Wuxi Beta Pharmaceutical Technology Co., Ltd., which is a major event and happy event in the history of the company's entrepreneurial development. Since then, Wuxi Beta has an excellent grasp and position for team building. In the next step, the Party branch of Wuxi Beta Pharmaceutical Technology Co., Ltd. will follow the "Articles of the Communist Party of China", "Regulations on the Work of the Communist Party of China (Trial)", and "Opinions of the Organization Department of the Jiangyin Municipal Committee of the Communist Party of China on Promoting the Construction of the" Jiyanghong "Pioneer Position Demonstration Project", "Jiangyin High-tech Zone" Two New "Organization Party Building Work Tackling Tackling Quality and Quality Action Plan" and other party regulations and policy documents, in

Wuxi Beta Won the Second Prize of China Jiangyin (High-tech Zone) Innovation and Entrepreneurship Competition in 2019

2019-06-17

In order to implement the innovation-driven development strategy, further promote "mass entrepreneurship and innovation", continuously expand the characteristic industries of the high-tech zone, accelerate the cultivation of innovative industrial clusters, continue to create an environment for innovation and entrepreneurship, and stimulate the vitality of innovation and entrepreneurship in the region, since May this year, Jiangyin Science and Technology and Talent work leading Group and Jiangyin National High-tech Zone jointly held the 2019 China Jiangyin (High-tech Zone) Innovation and Entrepreneurship Competition with the theme of Zhihui Jiangyin, the competition attracted more than 200 enterprises and teams from Beijing, Shanghai, Guangzhou, Shenzhen, Nanjing, Wuhan, Suzhou, Wuxi and other places. Wuxi Beta

Jiangsu Federation of Industry and Commerce-Wuxi Beta: Focus on Research and Development of "Carp into Dragon"

2019-04-15

Wuxi Beta: Focus on Research and Development of "Carp into Dragon" Source: Jiangyin Federation of Industry and Commerce Date: 2019-03-01 Website: http://www.jssh.org.cn/xxjlpt/sbxt/wxs/201903/t20190301_175211.html近日,位于江阴生物医药加速器的无锡贝塔医药科技有限公司与科伦药业子公司四川科伦药物研究院签订科技服务合作协议 。 Radioisotope labeling of Wuxi Beta by the head of the new drug research and development department of Sichuan Kelun Pharmaceutical Research Institute

Jiangyin Daily Digital News Platform-Wuxi Beta: Focus on Research and Development of "Translating Carp into Dragon"

2019-04-15

Wuxi Beta: Focus on Research and Development of "Carp into Dragon" Reporter Liu Xiao Website: http://cnepaper.com/jyrbszb/html/2019-03/01/content_5_1.htm近日,位于江阴生物医药加速器的无锡贝塔医药科技有限公司与科伦药业子公司四川科伦药物研究院签订科技服务合作协议 。 The head of the new drug research and development department of Sichuan Kelun Pharmaceutical Research Institute recognized Wuxi Beta's radioisotope labeling work and believed that Wuxi Beta was the Sichuan Kelun Pharmaceutical Research Institute in 2018.

Carbon -14 Marked Key Compound Preparation Technology Difficulties Overcome-China High-tech Network-China High-tech Industry Guide.

2019-04-15

Technical Difficulties in Preparation of Carbon -14 Marked Key Compounds Overcome 2019-03-2210:57:59 Source: Science and Technology Daily Author: Guo Guozhong Shen Wei Guo Yin Qingxi Website; http://www.chinahightech.com/html/yuanqu/yqcy/2019/0322/518171.html3月20日,江苏省江阴国家高新区发布了一项重点创新成果:该区无锡贝塔医药科技有限公司研发团队经过10年努力,攻克了碳-14标记关键化合物制备和标

< 12345 >